Accelerate Diagnostics Inc., alongside its US subsidiary, has filed for Chapter 11 bankruptcy as part of a restructuring effort. On May 30, 2025, the company entered into a "stalking horse" asset purchase agreement with an affiliate of Indaba Capital Management, L.P., its current secured noteholder. This agreement aims to sell substantially all of the company's assets. The transaction will be conducted under Section 363 of the Bankruptcy Code, requiring court approval and a bidding process to solicit potentially higher offers. The proceedings are accessible online through the company's claims agent, Stretto, Inc.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accelerate Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056448), on June 04, 2025, and is solely responsible for the information contained therein.
Comments